Loading...
IMTX logo

Immatics N.V.NasdaqCM:IMTX Stock Report

Market Cap US$1.2b
Share Price
US$9.87
My Fair Value
US$14
29.5% undervalued intrinsic discount
1Y-0.1%
7D-4.7%
Portfolio Value
​
View

Immatics N.V.

NasdaqCM:IMTX Stock Report

Market Cap: US$1.2b

Immatics (IMTX) Stock Overview

A clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. More details

IMTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 16.92% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years


IMTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Immatics N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Immatics
Historical stock prices
Current Share PriceUS$9.87
52 Week HighUS$11.25
52 Week LowUS$3.30
Beta1.22
1 Month Change63.68%
3 Month Change64.50%
1 Year Change-0.10%
3 Year Change-7.06%
5 Year Change-12.50%
Change since IPO2.81%

Recent News & Updates

Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel

Sep 19
Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth

Jun 22
We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth

Recent updates

Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel

Sep 19
Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth

Jun 22
We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth

Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S

May 17
Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S

Immatics N.V.: Trading Below Cash, But Not Without Reason

Mar 28

Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price

Jan 12
Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Sep 21
Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

Jul 12
Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

May 03
Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Sep 26
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Jun 12
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics launches $110M stock offering

Oct 10

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Jul 19

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Jan 29
Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Dec 16
Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Apr 01
Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Jan 18
What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Shareholder Returns

IMTXUS BiotechsUS Market
7D-4.7%2.8%1.7%
1Y-0.1%0.1%14.5%

Return vs Industry: IMTX matched the US Biotechs industry which returned 0.1% over the past year.

Return vs Market: IMTX underperformed the US Market which returned 14.5% over the past year.

Price Volatility

Is IMTX's price volatile compared to industry and market?
IMTX volatility
IMTX Average Weekly Movement9.9%
Biotechs Industry Average Movement10.6%
Market Average Movement6.5%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.0%

Stable Share Price: IMTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IMTX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a646Harpreet Singhwww.immatics.com

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.

Immatics N.V. Fundamentals Summary

How do Immatics's earnings and revenue compare to its market cap?
IMTX fundamental statistics
Market capUS$1.24b
Earnings (TTM)-US$87.23m
Revenue (TTM)US$151.84m
7.9x
P/S Ratio
-13.8x
P/E Ratio

Is IMTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMTX income statement (TTM)
Revenue€130.13m
Cost of Revenue€167.77m
Gross Profit-€37.64m
Other Expenses€37.11m
Earnings-€74.75m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.61
Gross Margin-28.93%
Net Profit Margin-57.45%
Debt/Equity Ratio0%

How did IMTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/17 19:18
End of Day Share Price 2025/10/17 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immatics N.V. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Eric SchmidtCantor Fitzgerald & Co.
Yevgeniya LivshitsChardan Capital Markets, LLC